Compare Spotify Technology (SPOT) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Spotify Technology vs Zimmer Biomet Holdings Inc — how do they compare? Spotify Technology trades at $528.22 (market cap $108.22B), while Zimmer Biomet Holdings Inc trades at $89.19 (market cap $16.95B). The key difference: Spotify Technology is far larger — about 6.4× Zimmer Biomet Holdings Inc's market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while Spotify Technology pays none. Which is the better fit depends on your goals — on Pluang, investors hold Spotify Technology for 111 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| SPOT | ZBH | |
|---|---|---|
Market Cap | $108.22B | $16.95B |
Volume | 1,655,796 | 2,505,240 |
Sector | Media | Health |
52-Week High | $692.04 | $103.98 |
52-Week Low | $412.75 | $79.58 |
Typical Hold Time | 111 Days | 89 Days |
Enterprise Value | $98.23B | $24.02B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Spotify (SPOT) trades at $529.14, up 3.16% with strong technical momentum above key support levels. The company demonstrates robust fundamental performance with revenue growth from $15.7B to $17.2B in 2025 and net income surging to $2.2B. Recent earnings show mixed results with two beats and one miss, while analyst consensus remains strongly bullish with a $606.50 price target. Technical indicators show bullish moving averages but neutral oscillators, with RSI suggesting potential overbought conditions near-term.
Spotify presents a compelling growth story with expanding profit margins and strong cash flow generation. Key opportunities include continued subscriber growth and new monetization tools, while risks involve competitive pressures and execution challenges. The stock trades near the lower end of analyst targets, offering potential upside if execution continues.
Zimmer Biomet (ZBH) trades at $88.70, up 0.24% on the day, with a bearish technical outlook but strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $2.07 exceeding expectations. Revenue growth remains steady, reaching $8.23B in 2025, while profitability metrics like a 69.87% gross margin and 9.48% net margin reflect operational efficiency. Recent corporate news includes a $0.24 quarterly dividend declaration and leadership promotions aimed at accelerating commercial transformation.
The investment outlook is mixed, with analyst consensus leaning hold (52.38%) but a price target of $103.11 suggesting 16% upside. Key opportunities include sustained earnings beats and strategic initiatives, while risks involve rising debt levels, competitive pressures, and technical bearish signals. The stock's current valuation at a P/E of 21.57 appears reasonable relative to growth prospects, but investors should weigh fundamental strength against near-term technical weakness and macroeconomic headwinds in the healthcare sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Spotify Technology
Spotify Technology S.A. provides music streaming services. The Company offers commercial-free music and ad-supported services to subscribers. Spotify Technology serves clients worldwide.
Read more on SPOT →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
